NasdaqGM - Delayed Quote USD

Clearside Biomedical, Inc. (CLSD)

1.2300

-0.0200

(-1.60%)

At close: 4:00 PM EDT

1.2400

+0.01

(+0.81%)

After hours: 7:21 PM EDT

Key Events

Loading Chart for CLSD

9/21 12:03 PM

DELL

Previous Close 1.2500
Open 1.2400
Bid 1.1800 x 100
Ask 1.2600 x 100
Day's Range 1.2100 - 1.2650
52 Week Range 0.6500 - 2.1200
Volume 109,173
Avg. Volume 383,439
Market Cap (intraday) 91.919M
Beta (5Y Monthly) --
PE Ratio (TTM) --
EPS (TTM) -0.5300
Earnings Date Aug 12, 2024 - Aug 16, 2024
Forward Dividend & Yield --
Ex-Dividend Date --
1y Target Est 5.50

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

clearsidebio.com

30

Full Time Employees

December 31

Fiscal Year Ends

Sector

Industry

Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

CLSD

5.13%

S&P 500

9.47%

1-Year Return

CLSD

17.14%

S&P 500

26.61%

3-Year Return

CLSD

49.80%

S&P 500

28.51%

5-Year Return

CLSD

4.24%

S&P 500

81.21%

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Clearside Biomedical, Inc.

1.2300

-1.60%

Mkt Cap 91.919M

Industry Biotechnology

Corvus Pharmaceuticals, Inc.

2.1100

+1.44%

Mkt Cap 131.983M

Industry Biotechnology

15.74

+1.94%

Mkt Cap 775.289M

Industry Biotechnology

0.8157

+5.76%

Mkt Cap 41.566M

Industry Biotechnology

Elevation Oncology, Inc.

3.5400

+7.93%

Mkt Cap 193.42M

Industry Biotechnology

Ocular Therapeutix, Inc.

5.64

-0.35%

Mkt Cap 873.574M

Industry Biotechnology

Aura Biosciences, Inc.

7.18

-1.78%

Mkt Cap 355.647M

Industry Biotechnology

Atara Biotherapeutics, Inc.

0.5564

+5.00%

Mkt Cap 66.999M

Industry Biotechnology

Kezar Life Sciences, Inc.

0.7475

-3.26%

Mkt Cap 54.419M

Industry Biotechnology

Lineage Cell Therapeutics, Inc.

1.0900

-6.84%

Mkt Cap 205.79M

Industry Biotechnology

Cara Therapeutics, Inc.

0.7503

+4.85%

Mkt Cap 41.017M

Industry Biotechnology

Valuation Measures

As of 5/10/2024

Market Cap

93.41M
Enterprise Value

65.51M
Trailing P/E

--
Forward P/E

--
PEG Ratio (5yr expected)

--
Price/Sales (ttm)

9.39
Price/Book (mrq)

--
Enterprise Value/Revenue

--
Enterprise Value/EBITDA

--

Financial Highlights

Profitability and Income Statement

Profit Margin

0.00%
Return on Assets (ttm)

-37.49%
Return on Equity (ttm)

--
Revenue (ttm)

8.45M
Net Income Avi to Common (ttm)

-34.97M
Diluted EPS (ttm)

-0.5300

Balance Sheet and Cash Flow

Total Cash (mrq)

35.35M
Total Debt/Equity (mrq)

--
Levered Free Cash Flow (ttm)

--

CLSD does not have Company Insights

CDTX Cidara Therapeutics, Inc.

12.70

+4.44%

LPTX Leap Therapeutics, Inc.

2.8300

+1.80%

CRVS Corvus Pharmaceuticals, Inc.

2.1100

+1.44%

VTVT vTv Therapeutics Inc.

25.90

-0.35%

ADVM Adverum Biotechnologies, Inc.

9.17

-1.40%

AKTX Akari Therapeutics, Plc

1.4900

-6.29%

EYEN Eyenovia, Inc.

0.8157

+5.76%

ACRS Aclaris Therapeutics, Inc.

1.1800

+0.85%

AGRX Agile Therapeutics, Inc.

0.3800

+1.20%

AFMD Affimed N.V.

5.26

+0.19%

AQST Aquestive Therapeutics, Inc.

3.2700

+5.83%

PIRS Pieris Pharmaceuticals, Inc.

11.33

+1.43%

DARE Daré Bioscience, Inc.

0.3152

+1.51%

ASLN ASLAN Pharmaceuticals Limited

0.4060

-1.22%

CTMX CytomX Therapeutics, Inc.

1.8900

-4.55%

XBIO Xenetic Biosciences, Inc.

3.9200

-0.76%